Literature DB >> 1815035

Evaluation of antibody-bearing liposomal amphotericin B in the treatment of systemic candidiasis in a neutropenic murine model.

T Belay1, D R Hospenthal, A L Rogers, M J Patterson.   

Abstract

The efficacy of liposomal amphotericin B bearing anticandidal antibodies (LAMB-Ab) was investigated in the treatment of systemic candidiasis in a murine model made neutropenic by an intraperitoneal injection of cyclophosphamide. Treatment with a single dose (0.6 mg amphotericin B kg-1 body weight) of LAMB-Ab resulted in an improved survival of neutropenic mice infected with Candida albicans compared to neutropenic mice treated with identical doses of liposomal amphotericin B or free amphotericin B.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1815035     DOI： 10.1080/02681219180000671

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN： 0268-1218


  4 in total

Review 1.  Biopharmaceutical aspects of lipid formulations of amphotericin B.

Authors:  G Storm; E van Etten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

2.  Disseminated trichosporonosis in a neutropenic murine model.

Authors:  D Hospenthal; T Belay; P Lappin; A Rogers; M Kennedy
Journal:  Mycopathologia       Date:  1993-05       Impact factor: 2.574

3.  Treatment of systemic candidiasis in a neutropenic murine model using immunoglobulin G bearing liposomal amphotericin B.

Authors:  T Belay; D R Hospenthal; A L Rogers; M J Patterson
Journal:  Mycopathologia       Date:  1993-07       Impact factor: 2.574

Review 4.  Optimizing efficacy of amphotericin B through nanomodification.

Authors:  Suresh P Vyas; Swati Gupta
Journal:  Int J Nanomedicine       Date:  2006
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.